Aliases:This biomarker is also known as:
- laminin receptor 1,
- 34/67 kDa laminin receptor,
- 40S ribosomal protein SA,
- Colon carcinoma laminin-binding protein,
- Multidrug resistance-associated protein MGr1-Ag,
- ribosomal protein SA,
- 67kD, ribosomal protein SA,
- Laminin-binding protein precursor p40,
- laminin receptor 1 (67kD, ribosomal protein SA),
Laminins, a family of extracellular matrix glycoproteins, are the major noncollagenous constituent of basement membranes. They have been implicated in a wide variety of biological processes including cell adhesion, differentiation, migration, signaling, neurite outgrowth and metastasis. Many of the effects of laminin are mediated through interactions with cell surface receptors. These receptors include members of the integrin family, as well as non-integrin laminin-binding proteins. The amino acid sequence of laminin receptor 1 is highly through evolution, suggesting a key biological function. It has been observed that the level of the laminin receptor transcript is higher in colon carcinoma tissue and lung cancer cell line than their normal counterparts. Also, there is a correlation between the upregulation of this polypeptide in cancer cells and their invasive and metastatic phenotype. Cell-adhesive protein LAMR1 plays an important role in the processes of cancer proliferation, invasion and metastasis. LAMR1 antigens have been found to be targets of autoantibodies in subjects newly diagnosed with lung cancer.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
LAMR1, previously found to be the target of autoantibodies in newly diagnosed subjects with lung cancer, is also associated with autoantibodies in sera collected at the pre-symptomatic stage. These findings suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens, including LAMR1.
The findings of this study suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens. Investigation of LAMR1 (RPSA) is ongoing.
Supporting Study Data
The following studies/protocols provide evidence supporting RPSA indications for the Lung…
Validation of Protein Markers for Lung Cancer Using CARET Sera and Proteomics Techniques
1.1 To validate the finding from pilot studies with CARET sera of autoantibodies to annexins I and II and PGP9.5 as potential biomarkers for lung cancers before the clinical diagnosis, evaluating sensitivity and specificity by time before diagnosis, treatment arm, gender, histologic type, and smoking status. 1.2 To determine whether a pattern of occurrence of autoantibodies in lung cancer sera may be diagnostic of lung cancer that is not dependent on the occurrence of any particular autoantibody. 1.3 To compare the findings for individual biomarker candidates and combinations of biomarker candidates in participants who were current smokers versus former smokers.View more about this study
Biomarker Characteristics Summary
|Notes||Sensitivity||Specificity||Prevalence||NPV||PPV||Specific Assay Type|
|Individual sera collected from 85 subjects within a year prior to a diagnosis of lung cancer and 85 matched controls from the CARET cohort were used in this analysis. Sam Hanash laboratory.||51.0||82.0||N/A||N/A||N/A|
Additional Study-Specific Protocols
No study-specific publications defined.
No organ-specific protocols defined.
No organ-specific publications defined.
No organ-specific resources defined.
No associated publications found.